Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome (MOSAIC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05933603 |
Recruitment Status :
Recruiting
First Posted : July 6, 2023
Last Update Posted : August 22, 2023
|
Tracking Information | |||||||
---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | June 26, 2023 | ||||||
First Posted Date ICMJE | July 6, 2023 | ||||||
Last Update Posted Date | August 22, 2023 | ||||||
Actual Study Start Date ICMJE | August 1, 2023 | ||||||
Estimated Primary Completion Date | August 2025 (Final data collection date for primary outcome measure) | ||||||
Current Primary Outcome Measures ICMJE |
obstructive apnea-hypopnea index (oAHI) [ Time Frame: 6 months ] change in number of obstructive apneas and hypopneas per hour on polysomnography from baseline (% change)
|
||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||
Change History | |||||||
Current Secondary Outcome Measures ICMJE |
|
||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||
Current Other Pre-specified Outcome Measures |
|
||||||
Original Other Pre-specified Outcome Measures |
|
||||||
Descriptive Information | |||||||
Brief Title ICMJE | Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome | ||||||
Official Title ICMJE | Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome | ||||||
Brief Summary | This is an open-label study of the combination of atomoxetine and oxybutynin (ato-oxy) in children with Down syndrome and obstructive sleep apnea (OSA) documented by polysomnography (PSG). Participants will receive ato-oxy for 6 months. Ato-oxy dose will be 5 mg oxybutynin and 0.5mg/kg/day (max 40 mg) atomoxetine. Dosing of the study treatment will occur approximately 30 minutes prior to bedtime. Participants who withdraw from the study will not be replaced. Study participants will undergo eligibility screening that will include an initial screening to determine whether non- PSG enrollment criteria are met, followed by a 1 night in-lab PSG and health-related quality of life (HRQOL) and cognitive assessment for participants who qualify based on non-PSG criteria. For participants who are eligible and enroll in the study, the screening PSG night will serve as the baseline measure for apnea hypopnea index (AHI) and other PSG endpoints. On the final night of dosing for ato-oxy participants will return for inpatient PSG and health-related quality of life assessment and cognitive assessment. The primary efficacy endpoint is the change in obstructive AHI from baseline. |
||||||
Detailed Description | Not Provided | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 2 | ||||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||||
Condition ICMJE |
|
||||||
Intervention ICMJE | Drug: Atomoxetine and Oxybutynin (ato-oxy)
0.5 mg/kg atomoxetine (max 40 mg) and 5 mg oxybutynin by mouth nightly
|
||||||
Study Arms ICMJE | Experimental: Ato-oxy
0.5 mg/kg (max 40 mg) atomoxetine and 5 mg oxybutynin
Intervention: Drug: Atomoxetine and Oxybutynin (ato-oxy)
|
||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Recruiting | ||||||
Estimated Enrollment ICMJE |
36 | ||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||
Estimated Study Completion Date ICMJE | December 2025 | ||||||
Estimated Primary Completion Date | August 2025 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
3. Absence of OSA defined as total AHI <5 on baseline polysomnography |
||||||
Sex/Gender ICMJE |
|
||||||
Ages ICMJE | 6 Years to 17 Years (Child) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE | |||||||
Listed Location Countries ICMJE | United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT05933603 | ||||||
Other Study ID Numbers ICMJE | 1908864846v2 R33HL151254 ( U.S. NIH Grant/Contract ) |
||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product |
|
||||||
IPD Sharing Statement ICMJE |
|
||||||
Current Responsible Party | University of Arizona | ||||||
Original Responsible Party | Same as current | ||||||
Current Study Sponsor ICMJE | University of Arizona | ||||||
Original Study Sponsor ICMJE | Same as current | ||||||
Collaborators ICMJE |
|
||||||
Investigators ICMJE | Not Provided | ||||||
PRS Account | University of Arizona | ||||||
Verification Date | June 2023 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |